FTC & PBMs: So What?
The FTC's August announcement of its settlement agreement with Merck/Medco Managed care outlined rules governing the PBM's relationaship with Merck & Co. Inc. The FTC's aggressive tone--which suggested that Medco acknowledged that past actions in promoting Merck drugs restricted competition and resulted in higher prices for some drugs--made the agreement seem like a victory for the FTC and upset Medco officials who concede no such things.
You may also be interested in...
Boston Scientific has agreed to pay $1.07bn to acquire Lumenis’ surgical laser business from Baring Private Equity Asia. See what Meghan Scanlon, president of Boston Scientific’s urology and pelvic health business, said about it here.
US Remains Conservative On Vaccine Dosing Regimens As CDC’s ACIP Highlights Minimal Comfort With Relying On Unproven Correlates
The Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices concerns about making COVID-19 vaccine dose regimen changes based on unproven immune correlates of protection could be a warning sign to sponsors about roadblocks they might face if updating vaccines to address viral variants or conducting pediatric studies relying on such surrogate endpoints.
J&J CEO Gorsky says the agency is working with sponsors to ensure the proper data is gathered to make the vaccine available in children.